The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 66 , ISSUE 2 ( April-June, 2024 ) > List of Articles

CASE REPORT

Superior Vena Cava Syndrome in Pulmonary Adenocarcinoma: A Rare Clinical Presentation and a Different Course of Management

Sanchit Mohan, Rohit Kumar, Nitesh Gupta, Pranav Ish

Keywords : Adenocarcinoma of the lung, Balloon dilatation, Case report, Superior vena cava syndrome

Citation Information : Mohan S, Kumar R, Gupta N, Ish P. Superior Vena Cava Syndrome in Pulmonary Adenocarcinoma: A Rare Clinical Presentation and a Different Course of Management. Indian J Chest Dis Allied Sci 2024; 66 (2):74-76.

DOI: 10.5005/jp-journals-11007-0115

License: CC BY-NC 4.0

Published Online: 10-07-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Superior vena cava syndrome (SVCS) can be associated with benign as well as malignant causes, NSCLC being the most common malignant cause and is rarely associated with adenocarcinoma of the lung. Symptoms may range from dyspnea to respiratory failure requiring urgent intervention. Endovascular stenting, radiotherapy, and treatment of underlying cancer are required to relieve symptoms. Balloon dilatation of SVC is usually done for SVC secondary to benign disease. We report a case of adenocarcinoma of the lung presenting with SVCS, which responded well to SVC dilatation and chemotherapy.


HTML PDF Share
  1. Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med 2007;356(18):1862–1869. DOI: 10.1056/NEJMcp067190.
  2. Kvale PA, Selecky PA, Prakash UB, et al. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):368S–403S. DOI: 10.1378/chest.07-1391.
  3. Yu JB, Wilson LD, Detterbeck FC. “Superior vena cava syndrome–A proposed classification system and algorithm for management”. J Thorac Oncol 2008;3(8):811–814. DOI: 10.1097/JTO.0b013e3181804791.
  4. Cheng S. “Superior vena cava syndrome: A contemporary review of a historic disease”. Cardiol Rev 2009;17(1):16–23. DOI: 10.1097/CRD.0b013e318188033c.
  5. Lanciego C, Pangua C, Chacon JI, et al. “Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome”. AJR Am J Roentgenol 2009;193(2):549–558. DOI: 10.2214/AJR.08.1904.
  6. Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implication and treatment strategies for the superior vena cava syndrome. Springerplus 2016,5:229. DOI: 10.1186/s40064-016-1900-7.
  7. Mineo TC, Ambrogi V, Nofroni I, et al. Mediastinoscopy in superior vena cava obstruction: Analysis of 80 consecutive patients. Ann Thorac Surg 1999;68(1):223–226. DOI: 10.1016/s0003-4975 (99)00455-5.
  8. Lepper PM, Ott SR, Hoppe H, et al. Superior vena cava syndrome in thoracic malignancies. Respir Care 2011;56(5):653–666. DOI: 10.4187/respcare.00947.
  9. Tzifa A, Marshall AC, McElhinney DB, et al. Endovascular treatment for superior vena cava occlusion or obstruction in a pediatric and young adult population: A 22-year experience. J Am Coll Cardiol 2007;49(9):1003–1009. DOI: 10.1016/j.jacc.2006.10.060.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.